CN115089562B - 一种抗菌医用疤痕贴及其制备方法 - Google Patents
一种抗菌医用疤痕贴及其制备方法 Download PDFInfo
- Publication number
- CN115089562B CN115089562B CN202210788858.3A CN202210788858A CN115089562B CN 115089562 B CN115089562 B CN 115089562B CN 202210788858 A CN202210788858 A CN 202210788858A CN 115089562 B CN115089562 B CN 115089562B
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- weight
- scar
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 122
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title abstract description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 87
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 38
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 38
- 229920002258 tannic acid Polymers 0.000 claims abstract description 38
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 38
- 229940033123 tannic acid Drugs 0.000 claims abstract description 38
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 38
- 235000011187 glycerol Nutrition 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 32
- 239000003906 humectant Substances 0.000 claims abstract description 32
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 30
- 239000000661 sodium alginate Substances 0.000 claims abstract description 30
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 30
- 229920000669 heparin Polymers 0.000 claims abstract description 28
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 28
- 229960001008 heparin sodium Drugs 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 26
- 239000012153 distilled water Substances 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 238000003756 stirring Methods 0.000 claims description 33
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical group COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 22
- 229940044631 ferric chloride hexahydrate Drugs 0.000 claims description 15
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims description 15
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 12
- 244000097577 Rhus javanica Species 0.000 claims description 12
- 235000010889 Rhus javanica Nutrition 0.000 claims description 12
- 229940041616 menthol Drugs 0.000 claims description 12
- 240000004980 Rheum officinale Species 0.000 claims description 11
- 235000008081 Rheum officinale Nutrition 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 229960001047 methyl salicylate Drugs 0.000 claims description 11
- 229920006264 polyurethane film Polymers 0.000 claims description 11
- -1 stirring uniformly Substances 0.000 claims description 11
- 244000292697 Polygonum aviculare Species 0.000 claims description 10
- 235000006386 Polygonum aviculare Nutrition 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 235000008390 olive oil Nutrition 0.000 claims description 6
- 239000004006 olive oil Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 3
- 241000034009 Lycopus Species 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 3
- 208000032544 Cicatrix Diseases 0.000 description 24
- 230000037387 scars Effects 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 24
- 238000011084 recovery Methods 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 16
- 239000011505 plaster Substances 0.000 description 15
- 206010052428 Wound Diseases 0.000 description 14
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 244000137773 Viola philippica Species 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000036573 scar formation Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000195954 Lycopodium clavatum Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000008350 Pruritus Vulvae Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241001517488 Clavus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001633628 Lycoris Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Insects & Arthropods (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Animal Husbandry (AREA)
Abstract
本发明提出了一种抗菌医用疤痕贴及其制备方法,涉及医药领域。一种抗菌医用疤痕贴,按重量份计,包括如下原料:单宁酸50‑90份、海藻酸钠1‑3份、甘油5‑8份、中药提取物5.1‑13.9份、抗菌剂1‑3份、保湿剂5‑10份、肝素钠0.01‑0.03份和蒸馏水90‑120份。此抗菌医用疤痕贴具有抗菌和祛疤效果。
Description
技术领域
本发明涉及医药领域,具体而言,涉及一种抗菌医用疤痕贴及其制备方法。
背景技术
“疤痕”是物理、生物和化学等因素的损害作用于人体皮肤软组织,导致皮肤软组织的严重损伤而不能完全自行正常修复,转由纤维组织替代修复留下的既影响外观又影响功能的局部症状。
增生性疤痕是皮肤各类创伤、烧伤、感染和手术等原因引起的病理性变化,是创面修复的重要过程,因其影响影响患者外观和功能,可以造成患者心理负担和痒痛不适。疤痕的形成机制尚未完全阐明,临床上仍缺乏简单有效的防治方法,目前还不能控制创面愈合进程而避免疤痕形成。
增生的瘢痕中胶原纤维的排列往往是不规则的,一般会异常凸出,呈漩涡形或绳索形,不仅影响患者外形美观,严重者会导致患者瘙痒、疼痛,更甚者会导致挛缩畸形、功能丧失等严重后果,使患者身心受到影响,影响其一生的生活。瘢痕的防治与美容整形,不仅是患者的刚性要求,也是医疗美容界研究的热点。目前学术界一致认为在瘢痕形成和增生阶段采取有效的防治措施,是预防瘢痕形成的关键。目前预防抑制疤痕增长的机制主要有水化作用、上皮化促进效应和压迫治疗机制。水化作用是指表皮组织水分含量过多时,会发生皮肤角质层水潴留,从而引发的一系列生理性变化。上皮化促进效应是指及时有效地促进上皮组织覆盖新生组织表面,可反馈性的抑制胶原的过度合成。压迫治疗机制是指在创伤修复过程中持续地在组织表面施加压力,可导致表面形成局域缺血、缺氧,降低组织代谢率,提高伤口内胶原酶活性,有利于促进胶原束分散和规则分布。这些作用机制会减少表皮毛细血管增生,降低胶原沉积,会减少瘢痕增生。
但是现有的疤痕贴缺少抑菌的作用,使得疤痕处可能由于微生物繁殖导致疤痕溃烂,进而使得疤痕增生,无法起到祛疤效果。并且现有的疤痕贴的祛疤效果也不明显,使用效果较差。
发明内容
本发明的目的在于提供一种抗菌医用疤痕贴,此抗菌医用疤痕贴具有抗菌和祛疤效果。
本发明的另一目的在于提供一种抗菌医用疤痕贴的制备方法,以获得此疤痕贴。
本发明解决其技术问题是采用以下技术方案来实现的。
一方面,本申请实施例提供一种抗菌医用疤痕贴,按重量份计,包括如下原料:单宁酸50-90份、海藻酸钠1-3份、甘油5-8份、中药提取物5.1-13.9份、抗菌剂1-3份、保湿剂5-10份、肝素钠0.01-0.03份、蒸馏水90-120份和氯化铁六水合物。
另一方面,本申请实施例提供一种抗菌医用疤痕贴的制备方法,包括如下步骤:将单宁酸溶解于蒸馏水中,向单宁酸中加入氯化铁六水合物,加热搅拌1-2h,加入海藻酸钠,搅拌1-1.5h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置3-5h,烘干,得到抗菌医用疤痕贴成品。
相对于现有技术,本发明的实施例至少具有如下优点或有益效果:
本发明通过以海藻酸钠为材料,制备成复合的凝胶材质的疤痕贴,能够具有较强的吸水性,可以将疤痕处渗出的组织液吸收,提供一个比较适宜疤痕恢复的环境,而且其具有良好的修复疤痕和抗菌的效果,还具有良好的生物相容性;添加的甘油可以增强整个疤痕贴的柔韧性,使得其贴服在疤痕处,粘合情况好;添加的中药提取物具有活血柔皮、软坚消散、消除疤痕和促进伤口恢复的积极效果;而抗菌剂能够对微生物起到杀灭作用,为疤痕处提供良好的恢复条件;保湿剂的使用能保持创口湿度环境,可以加速创口恢复,也能够减少疤痕的增生;肝素钠能够阻碍纤维蛋白原变成纤维蛋白,进而抑制疤痕的生成,进而起到消除疤痕的作用。整体作用,能够起到促进伤口愈合和消除疤痕的作用。
本发明的制备方法简单便捷,能够快速简单的制备出此抗菌医用疤痕贴。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。下面将参考具体实施例来详细说明本发明。
五倍子提取物:味酸、涩,性寒。有敛肺降火,涩肠止泻,敛汗止血,收湿敛疮之效。用于肺虚久咳,肺热痰嗽,久泻久痢,盗汗,消渴,便血痔血,外伤出血,痈肿疮毒,皮肤湿烂。
泽兰提取物:味苦、辛,性微温。有活血化瘀,行水消肿之效。用于月经不调,经闭,痛经,产后瘀血腹痛,水肿。
薄荷脑提取物:味辛,性凉。有疏风清热之效。主风热感冒,头痛,目赤,咽喉肿痛,齿痛,皮肤瘙痒。
大黄提取物:味苦,性寒。有泻热通肠,凉血解毒,逐瘀通经之效。用于实热便秘,积滞腹痛,泻痢不爽,湿热黄疸,血热吐衄,目赤,咽肿,肠痈腹痛,痈肿疔疮,瘀血经闭,跌打损伤,外治水火烫伤和上消化道出血。酒大黄善清上焦血分热毒,火毒疮疡。
鸦胆子提取物:味苦,性寒,有小毒。有清热解毒,截疟,止痢,腐蚀赘疣之效。外治赘疣,鸡眼。
紫花地丁提取物:味苦、辛,性寒。有清热解毒,凉血消肿之效。用于疔疮肿毒,痈疽发背,丹毒,毒蛇咬伤。
五爪金龙提取物:味辛,性温。有祛风除湿,接骨续筋,散瘀消肿之效。主风湿痹痛,跌打损伤骨折筋伤,水火烫伤,无名肿毒,皮肤湿烂。
萹蓄提取物:味苦,性微寒。有利尿通淋,杀虫,止痒之效。用于膀胱热淋,小便短赤,淋沥涩痛,皮肤湿疹,阴痒带下。
石香葇提取物:味辛、苦,性温。具有祛暑,活血,理气,化湿之效。用于夏季感冒,中暑呕恶,腹痛泄泻,跌打瘀痛,湿疹,疖肿。
苦参提取物:味苦,性寒。有清热燥湿,杀虫,利尿之效。用于热痢,便血,黄疸尿闭,赤白带下,阴肿阴痒,湿疹,湿疮,皮肤瘙痒,疥癣麻风;外治滴虫性阴道炎。
本发明提供一种抗菌医用疤痕贴,按重量份计,包括如下原料:
单宁酸50-90份、海藻酸钠1-3份、甘油5-8份、中药提取物5.1-13.9份、抗菌剂1-3份、保湿剂5-10份、肝素钠0.01-0.03份和蒸馏水90-120份。本发明通过以海藻酸钠为材料,制备成复合的凝胶材质的疤痕贴,能够具有较强的吸水性,可以将疤痕处渗出的组织液吸收,提供一个比较适宜疤痕恢复的环境,而且其具有良好的修复疤痕和抗菌的效果,还具有良好的生物相容性;添加的甘油可以增强整个疤痕贴的柔韧性,使得其贴服在疤痕处,粘合情况好;添加的中药提取物具有活血柔皮、软坚消散、消除疤痕和促进伤口恢复的积极效果;而抗菌剂能够对微生物起到杀灭作用,为疤痕处提供良好的恢复条件;保湿剂的使用能保持创口湿度环境,可以加速创口恢复,也能够减少疤痕的增生;肝素钠能够阻碍纤维蛋白原变成纤维蛋白,进而抑制疤痕的生成,进而起到消除疤痕的作用。整体作用,能够起到促进伤口愈合和消除疤痕的作用。
在本发明的一些实施例中,上述抗菌医用疤痕贴包括如下原料:
单宁酸70份、海藻酸钠2份、甘油7份、中药提取物9.5份、抗菌剂2份、保湿剂8份、肝素钠0.02份和蒸馏水105份。
在本发明的一些实施例中,上述中药提取物包括五倍子提取物0.5-2重量份、泽兰提取物1-1.5重量份、薄荷脑提取物0.5-1.5重量份、大黄提取物0.1-0.3重量份、鸦胆子提取物0.3-0.8重量份、紫花地丁提取物0.2-0.5重量份、五爪金龙提取物0.5-1.3重量份、萹蓄提取物0.5-1.5重量份、石香葇提取物0.5-1.5重量份和苦参提取物1-3重量份。
在本发明的一些实施例中,上述中药提取物包括五倍子提取物1.3重量份、泽兰提取物1.3重量份、薄荷脑提取物1重量份、大黄提取物0.2重量份、鸦胆子提取物0.5重量份、紫花地丁提取物0.3重量份、五爪金龙提取物0.9重量份、萹蓄提取物1重量份、石香葇提取物1重量份和苦参提取物2重量份。通过上述诸药协同作用,能够消炎解毒,促进组织再生,刺激上皮细胞生长,促进创面愈合,化瘀消肿,活血柔皮,去腐消疤,软坚消节,综合性的起到帮助伤口愈合且消除疤痕的作用。
在本发明的一些实施例中,上述抗菌剂为水杨酸甲酯。水杨酸甲酯具有镇痛、消炎和杀菌作用,能够抑制创口周围微生物繁殖,进而提供比较好的恢复环境。
在本发明的一些实施例中,上述保湿剂为聚乙二醇、橄榄油或丙三醇。聚乙二醇安全性高,不易刺激皮肤,且具有优秀的保湿性和吸水性,能够润湿皮肤,保持创面湿润,能够避免疤痕形成;橄榄油中含有角鲨烯,能够湿润皮肤,且对人体无刺激性,能够有效保湿;丙三醇具有优秀的吸湿性,能够软化皮肤,避免疤痕硬化。
本发明还提供一种抗菌医用疤痕贴的制备方法,包括如下步骤:
将单宁酸溶解于蒸馏水中,向单宁酸中加入氯化铁六水合物,加热搅拌1-2h,加入海藻酸钠,搅拌1-1.5h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置3-5h,烘干,得到抗菌医用疤痕贴成品。本发明的制备方法简单便捷,能够快速简单的制备出此抗菌医用疤痕贴。
在本发明的一些实施例中,上述氯化铁六水合物与单宁酸的摩尔比为1:(3-4)。
在本发明的一些实施例中,上述海藻酸钠加入前加热到70-85℃。
在本发明的一些实施例中,上述烘干具体是在35-55℃下烘干15-20h。在该条件下烘干能够保持其具有比较好的结构形状,同时不过于干燥,使得其具有比较好的使用性能。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
一种抗菌医用疤痕贴的制备方法,包括如下步骤:
原料:单宁酸50g、海藻酸钠1g、甘油5g、中药提取物(五倍子提取物0.5g、泽兰提取物1g、薄荷脑提取物0.5g、大黄提取物0.1g、鸦胆子提取物0.3g、紫花地丁提取物0.2g、五爪金龙提取物0.5g、萹蓄提取物0.5g、石香葇提取物0.5g和苦参提取物1g)5.1g、抗菌剂(水杨酸甲酯)1g、保湿剂(聚乙二醇)5g、肝素钠0.01g和蒸馏水90g。
将单宁酸溶解于蒸馏水中,按照1:3的摩尔比向单宁酸中加入氯化铁六水合物,加热到70℃搅拌1h,加入海藻酸钠,搅拌1h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置3h,在35℃下烘干15h,得到抗菌医用疤痕贴成品。
实施例2
一种抗菌医用疤痕贴的制备方法,包括如下步骤:
原料:单宁酸60g、海藻酸钠1.5g、甘油6g、中药提取物(五倍子提取物0.9g、泽兰提取物1.1g、薄荷脑提取物0.8g、大黄提取物0.2g、鸦胆子提取物0.4g、紫花地丁提取物0.3g、五爪金龙提取物0.7g、萹蓄提取物0.8g、石香葇提取物0.8g和苦参提取物1.2g)7.2g、抗菌剂(水杨酸甲酯)1.5g、保湿剂(聚乙二醇)6g、肝素钠0.02g和蒸馏水100g。
将单宁酸溶解于蒸馏水中,按照1:3的摩尔比向单宁酸中加入氯化铁六水合物,加热到75℃搅拌1.5h,加入海藻酸钠,搅拌1.2h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置4h,在40℃下烘干170h,得到抗菌医用疤痕贴成品。
实施例3
一种抗菌医用疤痕贴的制备方法,包括如下步骤:
原料:单宁酸70g、海藻酸钠2g、甘油7g、中药提取物(五倍子提取物1.3g、泽兰提取物1.3g、薄荷脑提取物1g、大黄提取物0.2g、鸦胆子提取物0.5g、紫花地丁提取物0.3g、五爪金龙提取物0.9g、萹蓄提取物1g、石香葇提取物1g和苦参提取物2g)9.5g、抗菌剂(水杨酸甲酯)2g、保湿剂(聚乙二醇)8g、肝素钠0.02g和蒸馏水105g。
将单宁酸溶解于蒸馏水中,按照1:4的摩尔比向单宁酸中加入氯化铁六水合物,加热到70-85℃搅拌1-2h,加入海藻酸钠,搅拌1.4h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置4.5h,在45℃下烘干18h,得到抗菌医用疤痕贴成品。
实施例4
一种抗菌医用疤痕贴的制备方法,包括如下步骤:
原料:单宁酸80g、海藻酸钠2.5g、甘油7g、中药提取物(五倍子提取物1.8g、泽兰提取物1.4g、薄荷脑提取物1.3g、大黄提取物0.2g、鸦胆子提取物0.6g、紫花地丁提取物0.4g、五爪金龙提取物1.1g、萹蓄提取物1.3g、石香葇提取物1.3g和苦参提取物2.5g)11.9g、抗菌剂(水杨酸甲酯)2.5g、保湿剂(聚乙二醇)9g、肝素钠0.02g和蒸馏水115g。
将单宁酸溶解于蒸馏水中,按照1:4的摩尔比向单宁酸中加入氯化铁六水合物,加热到80℃搅拌2h,加入海藻酸钠,搅拌1.5h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置5h,在45℃下烘干20h,得到抗菌医用疤痕贴成品。
实施例5
一种抗菌医用疤痕贴的制备方法,包括如下步骤:
原料:单宁酸90g、海藻酸钠3g、甘油8g、中药提取物(五倍子提取物2g、泽兰提取物1.5g、薄荷脑提取物1.5g、大黄提取物0.3g、鸦胆子提取物0.8g、紫花地丁提取物0.5g、五爪金龙提取物1.3g、萹蓄提取物1.5g、石香葇提取物1.5g和苦参提取物3g)13.9g、抗菌剂(水杨酸甲酯)3g、保湿剂(聚乙二醇)10g、肝素钠0.03g和蒸馏水120g。
将单宁酸溶解于蒸馏水中,按照1:4的摩尔比向单宁酸中加入氯化铁六水合物,加热到85℃搅拌2h,加入海藻酸钠,搅拌1.5h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置5h,在55℃下烘干20h,得到抗菌医用疤痕贴成品。
对比例1
本对比例与实施例3基本相同,区别在于:未添加中药提取物。
一种抗菌医用疤痕贴的制备方法,包括如下步骤:
原料:单宁酸70g、海藻酸钠2g、甘油7g、抗菌剂(水杨酸甲酯)2g、保湿剂(聚乙二醇)8g、肝素钠0.02g和蒸馏水105g。
将单宁酸溶解于蒸馏水中,按照1:4的摩尔比向单宁酸中加入氯化铁六水合物,加热到70-85℃搅拌1-2h,加入海藻酸钠,搅拌1.4h,再加入甘油、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置4.5h,在45℃下烘干18h,得到抗菌医用疤痕贴成品。
对比例2
本对比例与实施例3基本相同,区别在于:保湿剂为橄榄油。
一种抗菌医用疤痕贴的制备方法,包括如下步骤:
原料:单宁酸70g、海藻酸钠2g、甘油7g、中药提取物(五倍子提取物1.3g、泽兰提取物1.3g、薄荷脑提取物1g、大黄提取物0.2g、鸦胆子提取物0.5g、紫花地丁提取物0.3g、五爪金龙提取物0.9g、萹蓄提取物1g、石香葇提取物1g和苦参提取物2g)9.5g、抗菌剂(水杨酸甲酯)2g、保湿剂(橄榄油)8g、肝素钠0.02g和蒸馏水105g。
将单宁酸溶解于蒸馏水中,按照1:4的摩尔比向单宁酸中加入氯化铁六水合物,加热到70-85℃搅拌1-2h,加入海藻酸钠,搅拌1.4h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置4.5h,在45℃下烘干18h,得到抗菌医用疤痕贴成品。
对比例3
本对比例与实施例3基本相同,区别在于:保湿剂为丙三醇。
一种抗菌医用疤痕贴的制备方法,包括如下步骤:
原料:单宁酸70g、海藻酸钠2g、甘油7g、中药提取物(五倍子提取物1.3g、泽兰提取物1.3g、薄荷脑提取物1g、大黄提取物0.2g、鸦胆子提取物0.5g、紫花地丁提取物0.3g、五爪金龙提取物0.9g、萹蓄提取物1g、石香葇提取物1g和苦参提取物2g)9.5g、抗菌剂(水杨酸甲酯)2g、保湿剂(丙三醇)8g、肝素钠0.02g和蒸馏水105g。
将单宁酸溶解于蒸馏水中,按照1:4的摩尔比向单宁酸中加入氯化铁六水合物,加热到70-85℃搅拌1-2h,加入海藻酸钠,搅拌1.4h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置4.5h,在45℃下烘干18h,得到抗菌医用疤痕贴成品。
实验例
选取90只体重在200-250g、年龄为8周龄的SD大鼠,随机均分为9组,分别用实施例1-5和对比例1-3制备的抗菌医用疤痕贴,最后一组为空白对照组。
将大鼠注射3%戊巴比妥钠溶液麻醉,剪去背部毛发,用剪刀剪去2.5cm×2.5cm面积的背部皮肤,用碘酒进行消毒,在30天后,疤痕形成,观察疤痕情况,1-8组用抗菌医用疤痕贴贴敷治疗,9组用纱布包裹,观察伤口恢复情况和疤痕生长情况。
42天后处死大鼠,观察疤痕生长情况,将实验部位的皮肤剪下(3cm×3cm),将剪下的皮肤进行HE染色。
观察疤痕组织的颜色、质地、厚度和大小,并分别评价疤痕恢复情况,评级等级分为恢复良好、恢复一般和恢复较差。结果如表1所示。
恢复良好:疤痕面积明显变小,高度降低,质地柔软,颜色浅淡。
恢复一般:疤痕面积有所变小,高度降低部分,质地比较柔软,颜色变淡。
恢复较差:疤痕面积没有变化,高度没有降低,质地无变化,颜色无变化。
表1
组别 | 恢复良好/只 | 恢复一般/只 | 恢复较差/只 |
1组 | 9 | 1 | 0 |
2组 | 9 | 1 | 0 |
3组 | 10 | 0 | 0 |
4组 | 8 | 2 | 0 |
5组 | 9 | 1 | 0 |
6组 | 4 | 5 | 1 |
7组 | 8 | 2 | 0 |
8组 | 9 | 1 | 0 |
9组 | 0 | 5 | 5 |
分析表1,可以看出,本申请制备的抗菌医用疤痕贴对于疤痕的治疗效果好,能够有效减弱疤痕。
再计算疤痕增生指数HI,依据HI=A/B进行计算,A为疤痕凸起最高点到皮肤表面的垂直距离,B为疤痕周缘正常皮肤皮缘到兔皮肤表面的垂直距离,1-9组的疤痕增生指数如表2所示。
表2
组别 | 疤痕增生指数 |
1组 | 1.315±0.135 |
2组 | 1.215±0.115 |
3组 | 1.138±0.126 |
4组 | 1.195±0.135 |
5组 | 1.218±0.127 |
6组 | 2.351±0.136 |
7组 | 1.211±0.181 |
8组 | 1.204±0.119 |
9组 | 3.487±0.215 |
根据表2,可以看出,采用本申请制备的抗菌医用疤痕贴对于疤痕具有突出效果,且其中的中药提取物对于疤痕的减弱很重要。
综上所述,本发明通过以海藻酸钠为材料,制备成复合的凝胶材质的疤痕贴,能够具有较强的吸水性,可以将疤痕处渗出的组织液吸收,提供一个比较适宜疤痕恢复的环境,而且其具有良好的修复疤痕和抗菌的效果,还具有良好的生物相容性;添加的甘油可以增强整个疤痕贴的柔韧性,使得其贴服在疤痕处,粘合情况好;添加的中药提取物具有活血柔皮、软坚消散、消除疤痕和促进伤口恢复的积极效果;而抗菌剂能够对微生物起到杀灭作用,为疤痕处提供良好的恢复条件;保湿剂的使用能保持创口湿度环境,可以加速创口恢复,也能够减少疤痕的增生;肝素钠能够阻碍纤维蛋白原变成纤维蛋白,进而抑制疤痕的生成,进而起到消除疤痕的作用。整体作用,能够起到促进伤口愈合和消除疤痕的作用。
以上所描述的实施例是本发明一部分实施例,而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
Claims (7)
1.一种抗菌医用疤痕贴,其特征在于,按重量份计,由以下原料组成:
单宁酸50-90份、海藻酸钠1-3份、甘油5-8份、中药提取物5.1-13.9份、抗菌剂1-3份、保湿剂5-10份、肝素钠0.01-0.03份、蒸馏水90-120份和氯化铁六水合物,所述氯化铁六水合物与单宁酸的摩尔比为1:(3-4),所述抗菌剂为水杨酸甲酯;
所述中药提取物由以下原料组成,五倍子提取物0.5-2份、泽兰提取物1-1.5份、薄荷脑提取物0.5-1.5份、大黄提取物0.1-0.3份、鸦胆子提取物0.3-0.8份、紫花地丁提取物0.2-0.5份、五爪金龙提取物0.5-1.3份、萹蓄提取物0.5-1.5份、石香葇提取物0.5-1.5份和苦参提取物1-3份。
2.根据权利要求1所述的一种抗菌医用疤痕贴,其特征在于,所述抗菌医用疤痕贴包括如下原料:
单宁酸70份、海藻酸钠2份、甘油7份、中药提取物9.5份、抗菌剂2份、保湿剂8份、肝素钠0.02份和蒸馏水105份。
3.根据权利要求1所述的一种抗菌医用疤痕贴,其特征在于,所述中药提取物由以下原料组成,五倍子提取物1.3重量份、泽兰提取物1.3重量份、薄荷脑提取物1重量份、大黄提取物0.2重量份、鸦胆子提取物0.5重量份、紫花地丁提取物0.3重量份、五爪金龙提取物0.9重量份、萹蓄提取物1重量份、石香葇提取物1重量份和苦参提取物2重量份。
4.根据权利要求1所述的一种抗菌医用疤痕贴,其特征在于,所述保湿剂为聚乙二醇、橄榄油或丙三醇。
5.如权利要求1-4任意一项所述的一种抗菌医用疤痕贴的制备方法,其特征在于,包括如下步骤:
将单宁酸溶解于蒸馏水中,向单宁酸中加入氯化铁六水合物,加热搅拌1-2h,加入海藻酸钠,搅拌1-1.5h,再加入甘油、中药提取物、抗菌剂、肝素钠和保湿剂,搅拌均匀后,涂覆于聚氨酯膜上,静置3-5h,烘干,得到抗菌医用疤痕贴成品。
6.根据权利要求5所述的一种抗菌医用疤痕贴的制备方法,其特征在于,所述海藻酸钠加入前加热到70-85℃。
7.根据权利要求5所述的一种抗菌医用疤痕贴的制备方法,其特征在于,所述烘干具体是在35-55℃下烘干15-20h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210788858.3A CN115089562B (zh) | 2022-07-06 | 2022-07-06 | 一种抗菌医用疤痕贴及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210788858.3A CN115089562B (zh) | 2022-07-06 | 2022-07-06 | 一种抗菌医用疤痕贴及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115089562A CN115089562A (zh) | 2022-09-23 |
CN115089562B true CN115089562B (zh) | 2024-03-19 |
Family
ID=83297503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210788858.3A Active CN115089562B (zh) | 2022-07-06 | 2022-07-06 | 一种抗菌医用疤痕贴及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115089562B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105536027A (zh) * | 2015-12-24 | 2016-05-04 | 南阳市汇博生物技术有限公司 | 一种能够降低组织张力的疤痕贴及其制备方法 |
CN108030950A (zh) * | 2018-02-07 | 2018-05-15 | 苏州元禾医疗器械有限公司 | 一种祛除疤痕的创伤敷料 |
CN112316196A (zh) * | 2020-11-03 | 2021-02-05 | 辽宁燕阳医疗设备有限公司 | 一种含植物提取物的创面敷料及其应用 |
-
2022
- 2022-07-06 CN CN202210788858.3A patent/CN115089562B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105536027A (zh) * | 2015-12-24 | 2016-05-04 | 南阳市汇博生物技术有限公司 | 一种能够降低组织张力的疤痕贴及其制备方法 |
CN108030950A (zh) * | 2018-02-07 | 2018-05-15 | 苏州元禾医疗器械有限公司 | 一种祛除疤痕的创伤敷料 |
CN112316196A (zh) * | 2020-11-03 | 2021-02-05 | 辽宁燕阳医疗设备有限公司 | 一种含植物提取物的创面敷料及其应用 |
Non-Patent Citations (1)
Title |
---|
海藻酸钠基复合凝胶材料的制备及其抗菌与重金属离子吸附性能研究;于忠鹏;中国优秀硕士学位论文全文数据库;工程科技I辑(第08期);摘要,第9-10页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115089562A (zh) | 2022-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105194719A (zh) | 一种面部创口修复敷料、敷贴及其制备方法 | |
CN108186711A (zh) | 促进伤口愈合的药物组合物 | |
CN114099476A (zh) | 一种功能性凝胶层、疤痕贴及其制备方法 | |
CN103143054A (zh) | 一种消炎、促进伤口愈合的胶体敷料 | |
CN108686103B (zh) | 一种止血中药组合物以及多功能紧急止血复合材料 | |
CN115089562B (zh) | 一种抗菌医用疤痕贴及其制备方法 | |
CN105709273A (zh) | 一种含聚乙二醇的液体医用敷料 | |
CN111789912A (zh) | 一种红玉再生膏及其制备工艺 | |
WO2012100754A1 (zh) | 一种治疗刀伤、烧伤及多种创伤中药组合物 | |
CN112121146B (zh) | 一种用于皮肤创伤的外用凝胶剂及其制备方法 | |
CN103536959B (zh) | 一种肛肠病术后药用辅料贴的制作方法 | |
CN106937942A (zh) | 一种医用皮肤伤口镇痛凝胶及其制备方法 | |
US5616619A (en) | Topical composition for burn relief and method of use | |
CN113262264A (zh) | 一种用于止痛生肌的中药组合物及其制备方法 | |
CN111658716A (zh) | 一种水凝胶磁疗中药贴膏及其制备方法 | |
CN108355130A (zh) | 一种治疗牛皮癣的温敏型胶原复合消炎凝胶喷剂及其制备方法 | |
CN114632139B (zh) | 一种红霉素药膏及其制备方法 | |
CN108524294A (zh) | 一种面膜粉及其制备方法 | |
CN103181969B (zh) | 一种促进伤口愈合的中药组合物 | |
CN106421285A (zh) | 一种创面修复敷料 | |
RU2355411C1 (ru) | Ранозаживляющая мазь | |
CN100430078C (zh) | 一种含稀土的治疗烧创伤的药膏 | |
CN114010669A (zh) | 一种祛腐生肌软膏及其制备方法和应用 | |
CN115634251A (zh) | 一种芦荟凝胶创伤外用药的制备方法 | |
AU687840B2 (en) | Topical composition for burn relief and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |